http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
수중 가청음에 의한 쏨벵이의 청각능력 : 2. 청각 임계비
이창헌,박용석,문종욱,강창익,김고환,서두옥 제주대학교 해양연구소 1999 해양자원연구소연구보고 Vol.23 No.-
수중 가청음은 어군의 행동 제어와 해양목장화에서 음향 순치에 많이 이용되고 있다. 수중 가청음에 의한 어류반응 해석을 하기 위해서는 물고기의 청각능력을 정확히 파악할 필요가 있으며,오래전부터 여러물고기의 청각능력을 관련된 연구가 수행되었다.
혈액투석을 시행받고 있는 말기 신부전증 환자에서 투석 방법에 따른 피부색의 변화
김찬호 ( Chan Ho Kim ),강신욱 ( Shin Wook Kang ),문성진 ( Sung Jin Moon ),고광일 ( Kwang Il Ko ),김동현 ( Dong Hyun Kim ),김은영 ( Eun Young Kim ),박정탁 ( Jung Tak Park ),장태익 ( Tae Ik Chang ),김현욱 ( Hyun Wook Kim ),박선영 ( 대한신장학회 2008 Kidney Research and Clinical Practice Vol.27 No.5
Purpose: Skin hyperpigmentation in end stage renal disease patients is known to be attributed to the accumulation of middle molecular weight (MMW) substances such as urochromic pigments and carotenoids. Therefore, there is a possibility that hyperpigmentation may be improved by high-flux hemodialysis (HF-HD) and online hemodiafiltration (HDF). This prospective study was undertaken to investigate the quantitative changes in skin color in HD patients according to dialysis modality. Methods: Eighty-two stable ESRD patients undergoing HD were enrolled and divided into three groups according to their dialysis modality. Melanin index and erythema index of forearm and abdomen (non-sun exposed area), and forehead (sun exposed area) were measured by narrow-band reflectance spectrophotometer at baseline and after 12 months. Results: There were no significant differences in the baseline values of melanin and erythema indices among the three groups. But the changes in forehead melanin index were significantly lower in HDF patients (-1.0±2.4%) compared to the LF-HD group (0.3±1.6%) (p<0.05), and forehead erythema index was significantly decreased in patients treated by HDF (-1.6±2.5%) relative to the low-flux hemodialysis group (-0.1±2.5%) (p<0.05). Conclusion: The changes in skin color of sun exposed area were reduced by HDF, suggesting that enhanced removal of MMW substances by convective therapy may be of advantage to skin hyper-pigmentation in ESRD patients.
Chang-Keun Cho,Pureum Kang,Hye-Jung Park,Eunvin Ko,Chou Yen Mu,Yun Jeong Lee,Chang-Ik Choi,Hyung Sik Kim,Choon-Gon Jang,Jung-Woo Bae,Seok-Yong Lee 대한약학회 2022 Archives of Pharmacal Research Vol.45 No.5
Piroxicam is a non-steroidal anti-inflammatorydrug used to alleviate symptoms of osteoarthritis andrheumatoid arthritis. CYP2C9 genetic polymorphism significantly infl uences the pharmacokinetics of piroxicam. The objective of this study was to develop and validate thepiroxicam physiologically based pharmacokinetic (PBPK)model related to CYP2C9 genetic polymorphism. PK-Sim ®version 10.0 was used for the PBPK modeling. The PBPKmodel was evaluated by predicted and observed plasma concentration–time profi les, fold errors of predicted to observedpharmacokinetic parameters, and a goodness-of-fi t plot. Theturnover number (k cat ) of CYP2C9 was adjusted to capturethe pharmacokinetics of piroxicam in diff erent CYP2C9genotypes. The population PBPK model overall accuratelydescribed and predicted the plasma concentration–timeprofi les in diff erent CYP2C9 genotypes. In our simulations,predicted AUC inf in CYP2C9*1/*2 , CYP2C9*1/*3 , andCYP2C9*3/*3 genotypes were 1.83-, 2.07-, and 6.43-foldhigher than CYP2C9*1/*1 genotype, respectively. All fold error values for AUC, C max , and t 1/2 were included in theacceptance criterion with the ranges of 0.57–1.59, 0.63–1.39, and 0.65–1.51, respectively. The range of fold errorvalues for predicted versus observed plasma concentrationswas 0.11–3.13. 93.9% of fold error values were within thetwo-fold range. Average fold error, absolute average folderror, and root mean square error were 0.93, 1.27, and 0.72,respectively. Our model accurately captured the pharmacokineticalterations of piroxicam according to CYP2C9 geneticpolymorphism.
PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes
Chang-Keun Cho,Eunvin Ko,Ju Yeon Mo,Pureum Kang,Choon-Gon Jang,Seok-Yong Lee,Yun Jeong Lee,Jung-Woo Bae,Chang-Ik Choi 대한약학회 2024 Archives of Pharmacal Research Vol.47 No.1
Pantoprazole is used to treat gastroesophageal refl ux disease (GERD), maintain healing of erosive esophagitis (EE), andcontrol symptoms related to Zollinger–Ellison syndrome (ZES). Pantoprazole is mainly metabolized by cytochrome P450(CYP) 2C19, converting to 4′-demethyl pantoprazole. CYP2C19 is a genetically polymorphic enzyme, and the geneticpolymorphism aff ects the pharmacokinetics and/or pharmacodynamics of pantoprazole. In this study, we aimed to establishthe physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of pantoprazole in populationswith various CYP2C19 metabolic activities. A comprehensive investigation of previous reports and drug databases wasconducted to collect the clinical pharmacogenomic data, physicochemical data, and disposition properties of pantoprazole,and the collected data were used for model establishment. The model was evaluated by comparing the predicted plasmaconcentration–time profi les and/or pharmacokinetic parameters (AUC and C max ) with the clinical observation results. Thepredicted plasma concentration–time profi les in diff erent CYP2C19 phenotypes properly captured the observed profi les. All fold error values for AUC and C max were included in the two-fold range. Consequently, the minimal PBPK model forpantoprazole related to CYP2C19 genetic polymorphism was properly established and it can predict the pharmacokineticsof pantoprazole in diff erent CYP2C19 phenotypes. The present model can broaden the insight into the individualizedpharmacotherapy for pantoprazole.
Chang-Keun Cho,Ju Yeon Mo,Eunvin Ko,Pureum Kang,Choon-Gon Jang,Seok-Yong Lee,Yun Jeong Lee,Jung-Woo Bae,Chang-Ik Choi 대한약학회 2024 Archives of Pharmacal Research Vol.47 No.2
Pitavastatin, a potent 3-hydroxymethylglutaryl coenzyme A reductase inhibitor, is indicated for the treatment of hypercholesterolemiaand mixed dyslipidemia. Hepatic uptake of pitavastatin is predominantly occupied by the organic anion transportingpolypeptide 1B1 (OATP1B1) and solute carrier organic anion transporter family member 1B1 ( SLCO1B1 ) gene, which isa polymorphic gene that encodes OATP1B1. SLCO1B1 genetic polymorphism signifi cantly alters the pharmacokinetics ofpitavastatin. This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict pitavastatinpharmacokinetics according to SLCO1B1 genetic polymorphism. PK-Sim ® version 10.0 was used to establish the wholebodyPBPK model of pitavastatin. Our pharmacogenomic data and a total of 27 clinical pharmacokinetic data with diff erentdose administration and demographic properties were used to develop and validate the model, respectively. Physicochemicalproperties and disposition characteristics of pitavastatin were acquired from previously reported data or optimized to capturethe plasma concentration–time profi les in diff erent SLCO1B1 diplotypes. Model evaluation was performed by comparing thepredicted pharmacokinetic parameters and profi les to the observed data. Predicted plasma concentration–time profi les werevisually similar to the observed profi les in the non-genotyped populations and diff erent SLCO1B1 diplotypes. All fold errorvalues for AUC and C max were included in the two fold range of observed values. Thus, the PBPK model of pitavastatin indiff erent SLCO1B1 diplotypes was properly established. The present study can be useful to individualize the dose administrationstrategy of pitavastatin in individuals with various ages, races, and SLCO1B1 diplotypes.
Ko, Juhui,Lee, Sangyeop,Lee, Eun Kyu,Chang, Soo-Ik,Chen, Lingxin,Yoon, Soo-Young,Choo, Jaebum The Royal Society of Chemistry 2013 Physical chemistry chemical physics Vol.15 No.15
<P>A novel SERS-based sandwich immunoassay using DNA aptamers, silica-encapsulated hollow gold nanospheres (SEHGNs) and a gold-patterned microarray was developed for sensitive detection of VEGF (vascular endothelial growth factor) angiogenesis protein markers. Here, a DNA aptamer conjugated to SEHGN was used as a highly reproducible SERS-encoding nanoprobe, and a hybrid microarray including hydrophilic gold wells and other hydrophobic areas was used as a SERS substrate. Target specific DNA aptamers that fold into a G-quadruplex structure were used as a target recognition unit instead of VEGF antibodies. The detection sensitivity was increased by 2 or 3 orders of magnitude over the conventional ELISA method. In particular, the dynamic concentration range was 3 or 4 orders of magnitude greater than that of conventional ELISA. The results demonstrate that this sensing strategy using DNA aptamers is a powerful platform for the design of novel immune-sensors with high performance. In particular, SERS-based detection using SEHGNs provides great promise for highly sensitive biomarker sensing with unprecedented advantages.</P> <P>Graphic Abstract</P><P>We report a novel SERS-based sandwich immunoassay using DNA aptamer and a gold-patterned microarray for sensitive detection of VEGF angiogenesis protein markers. <IMG SRC='http://pubs.rsc.org/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=c2cp43155f'> </P>